North America Next Generation Antibody Therapeutics Market

North America Next-Generation Antibody Therapeutics Market Size (2023 to 2028):

The size of the North America Next-Generation Antibody Therapeutics Market is estimated to worth USD 3.44 billion by 2028 from USD 1.75 billion in 2023. It is expected to grow at a CAGR of 14.5% from 2023 to 2028.

Increased number of pharma, biopharma, and biotechnology companies are flourishingly investing in enhancing next-gen therapeutic antibodies opposite to autoimmune diseases, inflammatory disorders, and cancers, increasing utilization of antibody-drug conjugate (ADC) is the present trend over the market having positive vibrations for the market growth. Also, novel drug discoveries, a considerable number of government steps for the market growth, and growing acceptance for the drug discoveries are to surge the growth. In the U.S, an estimation of 1,735,350 new cancer cases is diagnosed, and 609,640 people lose their life due to this disease, according to the National Cancer Institute in 2018. Cancer accounts for 13% of the deaths every year, and a 70% surge in cancer occurrence is predicted for the next couple of years. Rising elder people population is projected to increase from 12% to 22% from 2015 to 2022 during the period.

Strict government regulations for the approval of antibody therapies are obstructing the market. High costs associated with therapies and the time required for the research and development activities are likely to hinder the market growth in the region.

This research report on the North America Next-Generation Antibody Therapeutics Market has been segmented and sub-segmented into the following categories

By Therapeutics:

• Oncology
• Autoimmune/Inflammatory Diseases

By Technology:

• Antibody-Drug Conjugates (ADCs)
• Bispecific Antibodies (BsAbs)
• Fc Engineered Antibodies
• Antibody Fragments
• Antibody-like Proteins
• Biosimilar Antibody Products

By Country:

• The United States
• Canada
• Rest of North America

Regional Analysis:

North America dominates the global next-generation antibody therapeutics market with the largest market share. The United States is the leader in the North American market. North America is ruling the next-generation antibody therapeutics market over the period in 2022. Factors like huge funds and investments for research and development and the rise in the aging population boost the growth in the market. The United States is leading the market of this region, followed by Canada. Regular increase of chronic diseases like cancer, asthma, and COPD and augment of old people population is propelling the market. Rising healthcare expenditure in developed and developing countries, advancements in technology are one of the key factors fueling the growth. For example, the development of glycoengineered antibody BsAbs and ADC technologies enlarged the application areas of antibody therapies. The robust appearance of established key players in the region and firmly developed life sciences research infrastructure are propelling the market growth. Canada is counted upon to have rapid growth in the market with the highest share. The government's support plays a vital role in research related to the next-gen antibody therapy, and extensive applications of those therapies are ascribed to bolster the market growth.

Key players dominating the North America Next-Generation Antibody Therapeutics Market include Roche, Seattle Genetics, Takeda, Dyax Corp., and Immunogen, Amgen, Inc., Biogen, Kyowa Hakko Kirin Co., Ltd., AstraZeneca, Pfizer, Inc., and Xencor, Inc.